Methodological and reporting quality of machine learning studies on cancer diagnosis, treatment, and prognosis.

This study aimed to evaluate the quality and transparency of reporting in studies using machine learning (ML) in oncology, focusing on adherence to the Consolidated Reporting Guidelines for Prognostic and Diagnostic Machine Learning Models (CREMLS), TRIPOD-AI (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis), and PROBAST (Prediction Model Risk of Bias Assessment Tool). The literature search included primary studies published between February 1, 2024, and January 31, 2025, that developed or tested ML models for cancer diagnosis, treatment, or prognosis. To reflect the current state of the rapidly evolving landscape of ML applications in oncology, fifteen most recent articles in each category were selected for evaluation. Two independent reviewers screened studies and extracted data on study characteristics, reporting quality (CREMLS and TRIPOD+AI), risk of bias (PROBAST), and ML performance metrics. The most frequently studied cancer types were breast cancer (n=7/45; 15.6%), lung cancer (n=7/45; 15.6%), and liver cancer (n=5/45; 11.1%). The findings indicate several deficiencies in reporting quality, as assessed by CREMLS and TRIPOD+AI. These deficiencies primarily relate to sample size calculation, reporting on data quality, strategies for handling outliers, documentation of ML model predictors, access to training or validation data, and reporting on model performance heterogeneity. The methodological quality assessment using PROBAST revealed that 89% of the included studies exhibited a low overall risk of bias, and all studies have shown a low risk of bias in terms of applicability. Regarding the specific AI models identified as the best-performing, Random Forest (RF) and XGBoost were the most frequently reported, each used in 17.8% of the studies (n = 8). Additionally, our study outlines the specific areas where reporting is deficient, providing researchers with guidance to improve reporting quality in these sections and, consequently, reduce the risk of bias in their studies.